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Abstract 1 
Background:  There is some evidence that the plasma vitamin E status is perturbed as part of the 2 
systemic inflammatory response and correcting this with other plasma markers may not lead to 3 
reliable results.  The aim of the present study was to examine the longitudinal inter-relationships 4 
between plasma and red blood cell vitamin α-tocopherol in patients with systemic inflammatory 5 
response syndrome.  6 
Methods:   α -tocopherol concentrations were measured, by HPLC, in plasma and red blood cells 7 
in normal subjects (n=67) and in critically-ill patients with systemic inflammatory response 8 
syndrome (n=82) on admission and on follow-up. 9 
Results:  Plasma α-tocopherol was significantly lower in the critically ill patients compared with 10 
the controls (all p<0.001) with 41% of patients having concentrations below the 95% confidence 11 
interval.  In contrast, when corrected for cholesterol, α-tocopherol concentrations were 12 
significantly higher in the critically ill patients compared with the controls group (p<0.001, 27% 13 
above the 95% confidence interval) and when corrected for triglycerides, α-tocopherol 14 
concentrations were significantly lower in the critically ill patients compared with the controls 15 
group (p<0.001).  Red blood cell α-tocopherol corrected for haemoglobin was similar (p=0.852) in 16 
the critically ill patients compared with control subjects.  The longitudinal measurements (n=53) 17 
gave similar results. 18 
Conclusions:  These results indicate that there is a discrepancy between vitamin E measurements 19 
in plasma, in plasma corrected for lipids and in red blood cells.  Although the value of correcting 20 
vitamin E concentrations by lipids is well established in population studies, the present study 21 
indicates that such correction is unreliable in the presence of systemic inflammatory response 22 
syndrome and that vitamin E status should be assessed using red blood cell α-tocopherol 23 
 3 
measurement. 1 
 4 
1.  Introduction 1 
There is increasing evidence that plasma concentrations of a number of important 2 
micronutrient biomarkers are influenced by the presence of a systemic inflammatory response [1-3 
3].  Such an effect has been reported in apparently healthy individuals [4-6], patients with chronic 4 
disease [7-11] and acute illness [12-14].  In particular, plasma concentrations of vitamins are 5 
reduced as part of the systemic inflammatory response in apparently healthy individuals [5], 6 
chronic disease [7-9, 15] and acute illness [12, 16-17] independent of status.  Some workers have 7 
proposed either correction of plasma vitamin concentrations [18-19] or measurement of 8 
intracellular vitamin concentrations [14, 20].   9 
Vitamin E is the major chain breaking lipophilic antioxidant in cell membranes and 10 
plasma, where it protects polyunsaturated fatty acids against free radical mediated peroxidation.  It 11 
is also essential, along with cholesterol, for the structural stability of membranes.  The most 12 
biological active form of vitamin E is α-tocopherol which accounts for more than 83% of the 13 
vitamin E in tissues [21].  Vitamin E status is usually assessed by measurement of α-tocopherol in 14 
plasma although its correlation in tissues is not clearly established.  Moreover, plasma 15 
concentrations of vitamin E are stongly associated with their carrier lipids, principally cholesterol 16 
and triglycerides.  To overcome this limitation it has been proposed the plasma α-tocopherol 17 
concentrations should be expressed in relation to plasma lipid levels, usually cholesterol [18-19, 18 
22]. 19 
Indeed, in healthy subjects undergoing elective surgery, there is a significant transient 20 
decrease in both α-tocopherol and cholesterol concentrations during the evolution of the systemic 21 
inflammatory response [5].  However, when the correction of plasma α-tocopherol by cholesterol, 22 
as proposed by Thurnham [19], was applied there was no significant alteration in plasma α-23 
 5 
tocopherol concentrations [5].  Moreover, we have observed that, in patients with systemic 1 
inflammatory response syndrome, when adjusted for cholesterol, α-tocopherol concentrations were 2 
significantly higher than controls [12].  Therefore, it would appear that the simple correction of α-3 
tocopherol for cholesterol may overestimate vitamin E status in patients with systemic 4 
inflammatory response syndrome.   5 
Since vitamin E is mainly present in cell membranes with plasma concentrations only 6 
representing a small fraction of total body vitamin E, it may be that measurement of red blood cell 7 
α-tocopherol concentrations will prove to be more reliable indicator of vitamin E status [23].  In 8 
animal studies, it has been reported that there is a good correlation between tissue and red blood 9 
cell α-tocopherol concentrations in the presence of variable plasma concentrations [24].  Also, red 10 
blood cell α-tocopherol concentrations have been used to assess vitamin E status in cystic fibrosis 11 
[25], in cigarette smoking [26], in type I diabetes [27] and in atherosclerosis [28].  Results from 12 
these studies showed significant correlations between red blood cell vitamin E status and markers 13 
of oxidative stress, or a dose response relationship in cases of supplementation.   14 
Therefore, the aim of the present study was to examine the longitudinal inter-relationships 15 
between α-tocopherol in the plasma, in the plasma corrected for lipids and in the red blood cell of 16 
patients with systemic inflammatory response syndrome.  17 
 6 
2.  Materials and Methods 1 
2.1  Patients and study design 2 
Patients in the Intensive Care Unit (ICU) of the Royal Infirmary, Glasgow, who had 3 
respiratory failure requiring ventilatory support, were ≥ 18 years old, and who had evidence of the 4 
systemic inflammatory response syndrome as per Bone’s criteria [29], were studied.  Venous 5 
blood samples (EDTA) were withdrawn on admission (day 1) and on follow–up (days 2-7) for the 6 
analysis of plasma and red blood cell α-tocopherol, C-reactive protein, albumin, cholesterol and 7 
triglycerides.  APACHE II score and predicted hospital mortality, SOFA score and B complex 8 
vitamin supplementation were recorded.  Enteral feeding was usually instituted on the second day 9 
in ICU. 10 
Patients received vitamin supplementation in ICU if they were considered clinically to be 11 
malnourished, had a history of excessive alcohol intake or were considered to have a general 12 
requirement for additional vitamin intake.  Supplementation was recorded from the drug cardex 13 
and given as Pabrinex  (Link Pharmaceuticals Ltd, West Sussex, UK) one dose of which contains 14 
500mg ascorbic acid, 160mg nicotinamide, 50mg pyridoxine hydrochloride, 4mg riboflavin, 15 
250mg thiamine hydrochloride.  No patient received vitamin E supplementation except for that 16 
contained in the standard commercially available enteral feeds, which was only in RDA amounts. 17 
With respect to the critically ill patients, the study was approved by the ethics committees 18 
of the North Glasgow NHS Trust and Multicentre Research Ethics Committee (MREC) Scotland.  19 
Where patients were unable to give signed informed consent, consent was obtained from the 20 
patients’ next of kin or welfare guardian in accordance with the requirements of the Adults with 21 
Incapacity Scotland Act (2000). 22 
 23 
 7 
2.2  Collection and preparation of blood samples 1 
The EDTA sample was centrifuged (500g, 4oC, 10mins) and plasma was removed into a 2 
plastic tube for vitamin determination, the buffy coat was discarded and packed red blood cells 3 
were washed with saline (NaCl 0.9%).  Red blood cells were centrifuged again and saline 4 
removed.  To lyse the red the cells 400µl of washed red blood cells were mixed with an equal 5 
volume of ascorbic acid solution (2%).  For long term storage of samples at -70o C, it was found 6 
necessary to stabilise the α-tocopherol in the haemolysate with ascorbic acid.  Under these 7 
conditions the α-tocopherol was stable for at least 6months.   8 
 9 
2.3  Measurement of plasma and red blood cell vitamin E 10 
Laboratory measurement of plasma and red blood cell α-tocopherol concentrations were 11 
determined by a high-performance liquid chromatography (HPLC) method [30].  Plasma and red 12 
blood cell α-tocopherol measurements in samples from the same patient were carried out in the 13 
same batch to minimise intra-patient measurement error.  Briefly, plasma was deproteinised with 14 
alcohol containing tocopherol acetate as an internal standard and extraction was performed using 15 
hexane.  HPLC analysis was carried out using a reverse-phase analytical column (5 µm C18; 3.2 x 16 
250mm, Nucleosil, Phenomenex, Macclesfield, UK) with UV monitoring at 295nm.  The limit of 17 
sensitivity for plasma α-tocopherol was 3 umol/ l.  The intra-assay coefficient of variation was less 18 
than 9% over the sample concentration range.   19 
Analysis of red blood cell α-tocopherol was performed using a modified procedure of 20 
Talwar et al. [30].  Eight hundred µl of the ascorbic acid stabilised haemolysate was thawed and 21 
after vortex mixing 400µl was used for α-tocopherol measurement with the remainder retained 22 
for haemoglobin (Hb) estimation.  For extraction of α-tocopherol from red blood cells, 400µl of 23 
 8 
the haemolysate was diluted with an equal volume of ascorbic acid (1%) and 100µl of internal 1 
standard (α-tocopherol nicotinate 50umol/l) added.  This mixture was deproteinised with 1.5ml 2 
of ethanol and the α-tocopherol was extracted twice with 3ml of hexane.  The hexane layer was 3 
removed and evaporated to dryness under a stream of air at 40ºC.  The residue was reconstituted 4 
with 100µl ethanol and 50µl injected onto the column via an autosampler.  The chromatographic 5 
conditions were as described above for plasma α-tocopherol [30].  Red blood cell concentration 6 
of α-tocopherol was based on a standard curve prepared by extracting ethanolic α-tocopherol 7 
standards as described above for red blood cell haemolysates. 8 
The concentration of α-tocopherol in red blood cells was also expressed as a ratio to 9 
haemoglobin concentrations (to improve the precision of the assay since the accurate pipetting 10 
of packed red blood cells is difficult, due to high viscosity, [31-32]).  The intra-assay coefficient 11 
of variation was 14% over the sample concentration range. 12 
Haemoglobin estimation was performed on an automatic analyser (Sapphire 350, Audit 13 
Diagnostics, Carrigtwohill, Ireland) using with Drabkins Reagent.  Haemoglobin is converted to 14 
Cynmethaemoglobin and the absorbance measured at the main wavelength of 546nm.  The 15 
within batch imprecision (CV%) was 0.95% at 6.9g/dL.  The between imprecision CV was 16 
4.7% at 7.1g/dL.  17 
 18 
2.4  Measurement of plasma protein and lipid concentrations 19 
Albumin, C-reactive protein, cholesterol and triglycerides were measured by routine 20 
laboratory procedures using an automated analyser (Architect, Abbott Diagnostics, USA).  The 21 
inter-assay coefficient of variation was less than 6% over the sample concentration range for these 22 
analytes.  23 
 9 
 1 
2.5  Statistics 2 
Data from normal subject and critically ill patient groups are presented as median and 3 
range.  Comparisons between the control and critically groups were performed with the use of the 4 
Mann-Whitney U test.  Correlations between variables in the critically ill group were performed 5 
with the use of the Spearman’s rank correlation.  Data from different time points in the patient 6 
groups were tested for statistical significance with the use of the Wilcoxon’s signed-rank test. 7 
Because of the number of statistical comparisons, a P value of<0.01 was considered to be 8 
significant.  Analysis was performed with the use of SPSS software (version 15; SPSS Inc, 9 
Chicago, Illinois, U.S.A.). 10 
 11 
 10 
3.0  Results 1 
In total, sixty seven healthy controls and eighty two critically ill patients (medical n=38, 2 
surgical n=44) were studied (Table 1).  The patients were not different in terms of age and sex 3 
compared with the controls.  The patients had median APACHE II score of 21, predicted hospital 4 
mortality of 36% and SOFA score of 7.  Patients had a median length of ICU stay of 6 days and 5 
median hospital stay of 23 days.   6 
The 95% reference intervals in the normal subjects for plasma α-tocopherol, plasma α-7 
tocopherol corrected for cholesterol, plasma α-tocopherol corrected for triglycerides and red blood 8 
cell α-tocopherol were 14-45 umol/ l, 2.36-48.00 umol/ mmol, 2.17-6.23 umol/ mmol and 7.8-30.8 9 
respectively.  Compared with controls, C-reactive protein concentrations were significantly higher 10 
and albumin concentrations were significantly lower in the critically ill patients group (both 11 
p<0.001).  Plasma cholesterol concentrations were significantly lower, but triglycerides were 12 
similar (p=0.218) in the critically ill patients compared with the controls (all p<0.001).  Plasma α-13 
tocopherol was significantly lower in the critically ill patients compared with the controls (all 14 
p<0.001) with 41% of patients having concentrations below the reference interval.  In contrast, 15 
when corrected for cholesterol, α-tocopherol concentrations were significantly higher in the 16 
critically ill patients compared with the controls group (p<0.001, 27% above the reference 17 
interval) and when corrected for triglycerides, α-tocopherol concentrations were significantly 18 
lower in the critically ill patients compared with the controls group (p<0.001).  Red blood cell α-19 
tocopherol corrected for haemoglobin was similar (p=0.852) in the critically ill patients compared 20 
with control subjects. 21 
The interrelationships between plasma and red blood cell concentrations of α-tocopherol, 22 
lipids and albumin in the control subjects are shown in Table 2.  Plasma α-tocopherol was directly 23 
 11 
associated with cholesterol (rs=0.35, p<0.01), triglycerides (rs=0.40, p<0.01) and inversely with 1 
albumin (rs=-0.46, p<0.01) but not red blood cell α-tocopherol corrected for haemoglobin.  Plasma 2 
α-tocopherol corrected for cholesterol was directly associated with red blood cell α-tocopherol 3 
corrected for haemoglobin (rs=0.51, p<0.01).   4 
The interrelationships between plasma and red blood cell concentrations of α-tocopherol, 5 
lipids and proteins in the critically-ill patients are shown in Table 3.  Plasma α-tocopherol was 6 
directly associated with cholesterol (rs=0.87, p<0.001), triglycerides (rs=0.66, p<0.001) and 7 
albumin (rs=0.60, p<0.001) but not red blood cell α-tocopherol corrected for haemoglobin at the 8 
p<0.01 level.  Plasma α-tocopherol corrected for cholesterol was inversely associated with 9 
albumin (rs=-0.41, p<0.01).  Plasma α-tocopherol corrected for triglycerides was directly 10 
associated with red blood cell α-tocopherol corrected for haemoglobin (rs=0.35, p<0.01).   11 
Of the 82 patients who were admitted to the intensive care unit, 53 had longitudinal 12 
measurements of both plasma and red blood cell α-tocopherol concentrations (Table 4).  Those 13 
patients with a follow-up sample had a higher APACHE II score than did those patients who did 14 
not (p<0.01).  The patients who did not have a longitudinal measurement were either discharged 15 
from ICU (n=28) or dead in ICU (n=1).  The time between admission and follow-up samples was 16 
a median of 4 days (range: 2–12 days).  There were no significant differences in plasma or red 17 
blood cell α-tocopherol concentrations between the admission values of those with and without a 18 
follow-up sample.  19 
Between the admission and follow-up measurements there was a decrease in albumin 20 
concentrations (p<0.01).  There was also a significant increase in α-tocopherol corrected for 21 
cholesterol (p<0.01), but no difference in -tocopherol corrected for triglycerides (p=0.117) or red 22 
 12 
blood cell α-tocopherol concentrations corrected for haemoglobin (p=0.066) at the p<0.01 level, 1 
between the admission and follow-up measurements. 2 
 3 
 13 
4.  Discussion 1 
 Plasma vitamin E (α-tocopherol) is most frequently used for assessing status although the 2 
relationship between plasma and tissue vitamin E concentrations has not been clearly established.  3 
In the plasma, α-tocopherol is recognised to circulate primarily bound to the lipoproteins in the 4 
lipid fraction, cholesterol and triglycerides [33].  It has been previously reported that where there 5 
are small changes in the circulating lipid fraction, plasma α-tocopherol concentrations are also 6 
altered [34].  Therefore, plasma α-tocopherol concentration corrected for lipids (whether 7 
cholesterol or triglycerides) is considered to be a more reliable measurement.  However, the basis 8 
for such a correction in the presence of systemic inflammation, where there are marked changes in 9 
plasma lipid concentration that occur as part of the acute phase response [35], has not been 10 
established.  11 
In the present study, compared with control subjects, the critically-ill patient group had 12 
lower plasma α-tocopherol concentrations and also when corrected for triglycerides.  In contrast, 13 
α-tocopherol concentrations were higher when corrected for cholesterol despite these patients 14 
receiving no vitamin E supplementation in their ITU.  Moreover, neither plasma α-tocopherol nor 15 
plasma α-tocopherol was strongly correlated with red blood cell α-tocopherol concentrations in the 16 
critically-ill patients.  Finally, median red  blood cell α-tocopherol concentrations were the same in 17 
the healthy subjects and patients with critical illness and systemic inflammatory response 18 
syndrome.  Taken together the results of the present study indicate that plasma α-tocopherol alone 19 
or corrected for lipids (cholesterol or triglycerides) is a less reliable marker of vitamin E status 20 
than red blood cell α-tocopherol in patients with a systemic inflammatory response. 21 
The low plasma α-tocopherol concentrations in critically ill patients with systemic 22 
inflammation are in agreement with previous reports [12, 16-17, 36-37].  However, the basis of the 23 
 14 
elevated plasma α-tocopherol when corrected for lipids is not clear.  From the present results, the 1 
basis appears to be due to the variable and disproportionately lower α-tocopherol (48%), 2 
cholesterol (61%) and triglyceride (15%) concentrations in the critically ill patients compared with 3 
controls.  These variable changes in α-tocopherol, cholesterol and triglycerides are such that when 4 
α-tocopherol was adjusted for cholesterol and triglycerides there were variable corrected values 5 
(31% higher and 43% lower, respectively).  Given that, in the plasma,  α-tocopherol is present in 6 
the greatest amount in the low density (LDL) and high density (HDL) lipoprotein fractions [38] 7 
and cholesterol concentration is markedly reduced whilst very low density lipoprotein (VLDL), 8 
and triglyceride not significantly so, this may have contributed to the variable and, we believe, 9 
unreliable estimation of α-tocopherol, when corrected for these lipid fractions. 10 
 In vitro studies have shown that whilst  α-tocopherol is transferred from all lipoprotein 11 
fractions to red blood cell membranes (and also presumably membranes of other cells), the relative 12 
ability to affect this transfer is 3 times greater with HDL and LDL (cholesterol) compared with 13 
VLDL (triglycerides) [39].  It is recognised that, as part of the systemic inflammatory response, 14 
the concentration and composition of plasma lipid and lipoproteins is markely altered.  In 15 
particular, plasma cholesterol concentrations are substantially reduced whereas plasma triglyceride 16 
concentrations are minimally reduced [35].  In the present study, critically-ill patients had a much 17 
reduced cholesterol/ triglyceride ratio compared with the controls largely due to the fall in plasma 18 
cholesterol concentration.  LDL, in man, is derived from VLDL and the two lipoprotein classes 19 
differ in that VLDL is larger and contains more triglyceride.  Therefore, in the presence of a 20 
systemic inflammatory response, it is likely that the transport of α-tocopherol is predominantly 21 
associated with triglyceride, that is VLDL protein rather the LDL protein, the concentration of 22 
which is relatively more reduced.  This may have resulted in a reduced transfer of α-tocopherol 23 
 15 
from plasma to cell membranes and/or reduced turnover of plasma α-tocopherol relative to plasma 1 
cholesterol.  As a result, in the presence of asystemic inflammatory response, plasma α-tocopherol 2 
concentration may fall less than cholesterol leading to increase in lipid corrected  α-tocopherol 3 
values in plasma.  Clearly, the analysis of α-tocopherol in the above lipid fractions in the presence 4 
of a systemic inflammatory response is required to test this hypothesis. 5 
In contrast, red blood cell α-tocopherol concentrations primarily reflect that in the red 6 
blood cell membrane [21] and therefore, less influenced by the acute changes in plasma lipid 7 
fractions as part of the systemic inflammatory response.  Indeed, Lehmann and coworkers [40], in 8 
normal subjects, reported that red blood cell α-tocopherol was more sensitive to dietary intake than 9 
the corresponding plasma measurement.  In addition, the susceptibility of red blood cells to 10 
haemolysis in the presence of hydrogen peroxide is more directly related to α-tocopherol 11 
concentration in red blood cells than in plasma.  Taken together these observations indicate that 12 
red blood cell α-tocopherol is a more reliable measure of vitamin E status.  13 
In summary, the results of the present study indicate that there is a discrepancy between 14 
vitamin E measurements in plasma, in plasma corrected for lipids and in red blood cells.  Although 15 
the value of correcting vitamin E concentrations by lipids is well established in population studies, 16 
the present study indicates that such correction is unreliable in the presence of systemic 17 
inflammatory response syndrome and that vitamin E status should be assessed using red blood cell 18 
α-tocopherol measurement.  19 
 20 
 16 
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Table 1.  Characteristics and vitamin E in critically-ill (medical and surgical) patients on 1 
admission (day 1) 2 
 
 
Healthy subjects 
(n= 67) 
Critically– ill patients 
Admission (n=82) 
p-value 
Age (yr) 55 (29-79) 60 (18-81) 0.123 
Sex (M/F) 36/ 31 52/ 30 0.233 
Medical/ Surgical   38/ 44  
Apache II  21 (3-38)  
Predicted mortality (%)  35.6 (1.2-92.6)  
SOFA score  7 (1-18)  
ICU Length of stay  6 (0.2-76.4)  
Hospital Length of stay  23 (0.4-508)  
Alive/ Dead  62/ 20  
Plasma    
C-reactive protein (mg/ l) <6 (<6-<6) 110 (<6-565) <0.001 
Albumin (g/ l) 44 (38-50) 18 (9-45) <0.001 
Cholesterol (mmol/ l) 5.40 (3.10-7.80) 2.10 (0.40-6.40) <0.001 
Triglycerides (mmol/ l) 1.25 (0.50-4.05) 1.06 (0.30-5.05) 0.218 
α-tocopherol (umol/ l) 29 (14-47) 15 (4-41) <0.001 
α-tocopherol/ chol (umol/ mmol) 5.19 (3.54-8.71) 6.82 (3.59-15.72) <0.001 
α-tocopherol/ triglycerides (umol/ mmol) 22.27 (7.16-67.27) 12.81 (4.82-47.79) <0.001 
Red blood cell    
α-tocopherol/ Hb (nmol/gHb) 18.5 (12-28)a 18.6 (3.4-39.3) 0.852 
Median (range), a  n=26 3 
 4 
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Table 2.  The relationship between plasma and red blood cell vitamin E concentrations in the control population (n= 67) 1 
 2 
 Plasma α-
tocopherol/ 
cholesterol 
Plasma α-
tocopherol/ 
triglycerides 
Plasma 
Cholestero
l 
Plasma 
Triglycerides 
Plasma 
Albumin 
Red blood cell 
α-tocopherol/ 
Hb 
Plasma       
α-tocopherol 0.68*** 0.00 0.35** 0.40** -0.46** 0.32a  
α-tocopherol/ 
cholesterol 
 0.11 -0.39** 0.15 -0.50** 0.51a ** 
α-tocopherol/ 
triglycerides 
  -0.09 -0.88*** -0.06 0.26 
Cholesterol    0.26* 0.03 -0.07a 
Triglycerides     -0.03 -0.10a 
 3 
a
 (n=26),  *P<0.05, ** P<0.01, *** P<0.001, Correlations between variables in the critically-ill group were carried out using the 4 
Spearman rank correlation (rs) 5 
 24 
Table 3.  The relationship between laboratory characteristics, plasma and red blood cell vitamin E concentrations in critically-1 
ill patients on admission to ICU (n=82) 2 
 3 
 Plasma α-
tocopherol/ 
cholesterol 
Plasma α-
tocopherol/ 
triglycerides 
Plasma 
Cholesterol 
Plasma 
Triglycerides 
Plasma 
Albumin 
Red blood cell 
α-tocopherol/ Hb 
Plasma       
α-tocopherol -0.12 0.17 0.87*** 0.66*** 0.60*** 0.23* 
α-tocopherol/ cholesterol  -0.15 -0.55*** -0.02 -0.41*** 0.29* 
α-tocopherol/ triglycerides 
  0.22 -0.57*** 0.16 0.35** 
Cholesterol    0.54*** 0.72*** 0.07 
Triglycerides     0.37*** -0.04 
 4 
*P<0.05, ** P<0.01, *** P<0.001, Correlations between variables in the critically-ill group were carried out using the Spearman rank 5 
correlation (rs) 6 
 7 
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Table 4.  Patient characteristics and vitamin E concentrations in critically ill patients on 1 
admission (day 1) and at follow-up 2 
 3 
 Critically ill patients 
Admission (n=53)
 
Critically ill patients 
Follow-up (n=53) 
P-value 
Age (yr) 61 (18-81)   
Sex (M/F) 37/ 16   
Patients (medical/ surgical) 25/ 28   
Apache II 23 (7-38)   
Predicted mortality (%) 42.5 (4.3-92.6)   
SOFA score 7 (1-14) 7 (0-13) 0.212 
ICU length of stay 10.3 (0.90-76.4)   
Hospital length of stay 27.5 (6-253)   
Alive/ Dead 34/ 19   
 
   
Plasma 
   
C-reactive protein (mg/ l) 96 (26-565) 136 (20-356) 0.270 
Albumin (g/ l) 16 (9-45) 14 (9-29) 0.001 
Cholesterol (mmol/ l) 1.70 (0.53-5.20) 1.80 (0.60-4.40) 0.565 
Triglycerides (mmol/ l) 0.80 (0.30-3.40) 1.02 (0.20-3.20) 0.575 
α-tocopherol (umol/ l) 14 (5-41) 16 (6-36) 0.081 
α-tocopherol/cholesterol (umol/ mmol) 7.21 (3.59-15.72) 8.20 (3.37-12.86) 0.010 
α-tocopherol/ triglycerides (umol/ mmol) 13.57 (4.82-47.79) 15.00 (3.73-60.05) 0.117 
Red blood cell 
   
α-tocopherol/ Hb (nmol/gHb) 19.04 (3.40-39.28) 21.86 (8.18-48.37) 0.066 
 4 
 5 
